Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts Sells 600 Shares

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of Penumbra stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $244.49, for a total transaction of $146,694.00. Following the completion of the transaction, the executive vice president now owns 63,444 shares in the company, valued at $15,511,423.56. This trade represents a 0.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Johanna Roberts also recently made the following trade(s):

• On Monday, November 18th, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $239.74, for a total value of $143,844.00.
• On Tuesday, October 1st, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $190.76, for a total value of $114,456.00.

Penumbra Stock Down 2.6 %

NYSE PEN opened at $242.70 on Friday. Penumbra, Inc. has a 1-year low of $148.00 and a 1-year high of $277.34. The company has a market capitalization of $9.31 billion, a price-to-earnings ratio of 282.21, a PEG ratio of 2.47 and a beta of 0.51. The stock’s 50 day moving average is $221.10 and its two-hundred day moving average is $199.69. The company has a current ratio of 5.82, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02.

Penumbra (NYSE:PEN) last posted its earnings results on Wednesday, October 30th. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.69 by $0.16. Penumbra had a return on equity of 8.99% and a net margin of 2.97%. The business had revenue of $301.04 million during the quarter, compared to the consensus estimate of $297.36 million. During the same quarter last year, the company earned $0.67 EPS. Penumbra’s revenue was up 11.1% on a year-over-year basis. Equities analysts forecast that Penumbra, Inc. will post 2.81 earnings per share for the current fiscal year.

Penumbra announced that its board has authorized a stock buyback program on Tuesday, August 13th that permits the company to repurchase $200.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 2.6% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Institutional Investors Weigh In On Penumbra

Large investors have recently made changes to their positions in the company. Tidal Investments LLC boosted its position in Penumbra by 276.9% in the first quarter. Tidal Investments LLC now owns 4,971 shares of the company’s stock valued at $1,109,000 after buying an additional 3,652 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Penumbra in the second quarter valued at approximately $17,943,000. Thrivent Financial for Lutherans boosted its holdings in shares of Penumbra by 3,832.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company’s stock worth $71,564,000 after acquiring an additional 358,932 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in Penumbra during the 3rd quarter worth approximately $1,092,000. Finally, AlphaCentric Advisors LLC acquired a new stake in Penumbra during the 3rd quarter valued at $777,000. Institutional investors own 88.88% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on the company. Stifel Nicolaus assumed coverage on Penumbra in a research report on Tuesday, September 17th. They issued a “buy” rating and a $238.00 price target on the stock. Canaccord Genuity Group boosted their target price on shares of Penumbra from $176.00 to $235.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Robert W. Baird upped their target price on shares of Penumbra from $244.00 to $248.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. Royal Bank of Canada raised their price target on shares of Penumbra from $205.00 to $222.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Finally, Citigroup upped their price objective on shares of Penumbra from $178.00 to $200.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $230.92.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.